Filter posts

Who Cares About ALS?

1,100 days. That’s the average amount of time a person survives following a diagnosis of …

Biomedical R&D in the 21st Century

Reflecting back upon my career,  I recognize the importance academic-industry research partnerships played in shaping …

Patients are the Missing Link in R&D

An architect does not wait until construction begins to show clients a blueprint. Neither does a caterer …

How to Survive the Patent Cliff: Eli Lilly’s CEO at the BIO CEO & Investor Conference

Like a number of companies, Eli Lilly is confronting a wave of patent expirations called …

Auto Injectors & Pen Injectors: Differentiating Products in Asia Pacific

Asia Pacific, with its mix of mature and emerging pharmaceutical markets and strong indigenous R&D …

Data Exclusivity Protects Innovators and Assures Investors

Biotechnology companies must have some certainty that they can protect their investment in the development …

Research: Working Together Toward Cures

Modern biomedical innovation and the discovery of new cures and therapies for devastating diseases require …

BIO 2012 Super Session Recap: Ernst & Young’s Beyond Borders

The fanfare surrounding this morning’s unveiling of Ernst & Young’s 26th annual report on the …

Fireside Chat with Dr. Mikael Dolsten

Day two of the BIO CEO & Investor Conference kicked off with a Fireside Chat …

Fireside Chat with Moncef Slaoui, GlaxoSmithKline

Moncel Slaoui, chairman of research and development (R&D) at GlaxoSmithKline (GSK), opened the 2012 BIO …